

atypical antipsychotics? A new hypothesis. *American Journal of Psychiatry*, **158**, 360–369.

**Olsson, H. & Farde, L. (2001)** Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D<sub>2</sub> receptor occupancy – a simulation study based on experimental data. *Neuroimage*, **14**, 936–945.

**Seeman, P. & Ulpian, C. (1983)** Neuroleptics have identical potencies in human brain limbic and putamen regions. *European Journal of Pharmacology*, **94**, 145–148.

—, **Corbett, R. & Van Tol, H. H. (1997)** Atypical neuroleptics have low affinity for dopamine D<sub>2</sub> receptors or are selective for D<sub>4</sub> receptors. *Neuropsychopharmacology*, **16**, 93–110; discussion 111–135.

**Xiberas, X., Martinot, J. L., Mallet, L., et al (2001)** Extrastriatal and striatal D<sub>2</sub> dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. *British Journal of Psychiatry*, **179**, 503–508.

**S. Kapur, P. Seeman** Centre for Addiction and Mental Health, The University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8

### Diagnosis of vascular dementia

I read Dr Stewart's article on vascular dementia (Stewart, 2002) with great interest. As a recently appointed consultant in old age psychiatry (having been trained in the 'old' way about diagnosing vascular dementia, i.e. sudden onset, stepwise deterioration, history of vascular risk factors, etc.), I started noticing a very different presentation of vascular dementia, especially in those with evidence of extensive periventricular disease on computed tomography. These cases commonly present with a range of frontal executive function deficits, with functional psychiatric symptoms of anxiety and depression and sometimes with progressive aphasia, and do not necessarily have the classical history of vascular dementia as described in textbooks.

The importance of the clinical findings is that as clinicians and educational supervisors we need to use more screening tests for frontal executive functions in routine assessments of dementia. In addition to the Mini-Mental State Examination (Folstein *et al*, 1975), verbal fluency and similarities (FAS; Thomas & O'Brien, 2002) tests are quick ways of testing frontal functions and should be encouraged among all members of a multi-disciplinary team. This has also been recognised in the new Cambridge Examination for Mental Disorder of the Elderly, Revised (CAMDEX-R; Roth *et al*, 1999).

Findings of periventricular ischaemia are controversial as far as their relevance to dementia diagnosis is concerned but patients who present with marked frontal functioning deficit and evidence of periventricular ischaemia on computed tomography should receive a diagnosis of vascular dementia. It is now known that ischaemia in periventricular areas interferes with the cortico-striato-thalamo-cortical loops which, in turn, affect functioning of frontal lobes.

**Folstein, M. F., Folstein, S. E. & McHugh, P. R. (1975)** 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*, **12**, 189–198.

**Roth, M., Huppert, P. A., Mountjoy, C., et al (1999)** *Cambridge Examination for Mental Disorder of the Elderly, Revised*. Cambridge: Cambridge University Press.

**Stewart, R. (2002)** Vascular dementia: a diagnosis running out of time. *British Journal of Psychiatry*, **180**, 152–156.

**Thomas, A. J. & O'Brien, J. T. (2002)** Alzheimer's disease. In *Psychiatry in the Elderly* (eds R. Jacoby & C. Oppenheimer), pp. 513–514. Oxford: Oxford University Press.

**S. Sikdar** Mersey Care NHS Trust, Waterloo Day Hospital, Park Road, Waterloo, Liverpool L22 3XR, UK

### Prolonged QT interval with rivastigmine

Rivastigmine is an acetylcholinesterase inhibitor licensed in the UK since 1998 for the treatment of mild to moderate Alzheimer's disease. Prolonged QT interval in association with this drug has not been previously described in the literature.

A 78-year-old man with dementia was commenced on rivastigmine for worsening of his cognitive decline and behavioural difficulties. He was receiving the following long-term medication: diltiazem, citalopram, furosemide, aspirin and ranitidine. His urea and electrolytes showed a low-normal potassium of 3.4 mmol/l (normal 3.5–5 mmol/l). A pre-treatment electrocardiogram (ECG) showed evidence of an old inferior myocardial infarct, a QT interval of 382 ms and a QTc interval of 397 ms.

Seven days after commencement of rivastigmine a repeat ECG showed a QT interval of 476 ms and a QTc interval of 477 ms. Rivastigmine was the only recent additional medication and was therefore discontinued. No other changes were made. One week later the ECG showed a normal

QT interval of 402 ms and a QTc interval of 399 ms. (An abnormal QTc interval is defined as >456 ms.) A repeat ECG 2 months later on his long-standing medication showed normal QT and QTc intervals.

Prolonged cardiac repolarisation (QT interval) is important as it may lead to potentially life-threatening ventricular arrhythmias (e.g. torsades de pointes; Thomas, 1994). Risk factors for prolonged QT intervals include: congenital long QT interval syndrome, clinically significant bradycardia or heart disease, electrolyte imbalance (hypokalaemia, hypomagnesaemia), impaired hepatic or renal function and concomitant treatment with drugs with potential for pharmacokinetic/pharmacodynamic interactions (De Ponti *et al*, 2000).

To date, rivastigmine has been associated in very rare cases with atrioventricular block (see Exelon product data sheet; Novartis Pharmaceuticals UK Ltd, 2001). A literature search failed to identify any reports of QT interval prolongation associated with rivastigmine.

Confounding factors, such as comedication, electrolyte abnormalities and underlying disease, are more likely to occur in older people, who are the most likely age group to be receiving these drugs. Case reports such as this are an important method of reporting potential side-effects, particularly in the context of a newly introduced therapy.

**De Ponti, F., Poluzzi, E. & Montanaro, N. (2000)** QT interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. *European Journal of Clinical Pharmacology*, **56**, 1–18.

**Novartis Pharmaceuticals UK Ltd (2001)** *Exelon*. Camberley: Novartis. Available at <http://jemc.vhn.net>.

**Thomas, S. H. (1994)** Drugs, QT interval abnormalities and ventricular arrhythmia: a record linkage study. *Adverse Drug Reactions and Toxicological Reviews*, **13**, 77–102.

**E. Walsh** Department of Liaison Psychiatry, Stobhill Hospital, 133 Balornock Road, Glasgow G21 3UW, UK

**J. Dourish** Leverndale Hospital, Glasgow, UK

### From mental hospitals to community care

The statistics on mental hospital closures given by Professor Leff (2001) will surprise not only lay people. I had no idea that hardly any mental hospital beds remain.